Skip to main content

Table 2 Comparison of high-dose intravenous immunoglobulin (IVIG) therapy and thrombopoietin receptor agonist (TPO-RA)

From: Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report

Characteristic IVIG therapy TPO-RA
Time of the beginning of the increase 3–4 days 5–7 days
Time before reaching the maximum 7 days 12–16 days
Effective rate 70–90% 80%
Validity 2–4 weeks 2 weeks
Rate of platelet transfusion avoidance (−) 72%
Adverse events Headache, fever, nausea Cytopenia
Muscle pain, general malaise Arterial and venous thrombosis
Aseptic meningitis Bone marrow reticulin fibrosis
Acute renal failure Rebound thrombocytopenia after discontinuation (platelet decrease relative to baseline)
Infection (HCV, HIV, etc.) Increases of ALT concentration
Thrombosis Headache
Cerebral infarction  
Pulmonary infarction  
Cost Venoglobulin IH® 5% IV REVOLADE® Tablets 12.5 mg 22.61 USD/tablet
5 g/100 mL = 349.62 USD/vial REVOLADE® Tablets 25 mg 44.55 USD/tablet
In case, 400 mg/kg/day, 50 kg In our case, preoperative for 23 days, 25 mg/day
349.62 × 4 vial × 5 days + postoperative 30 days
= 6992.35 USD = 2396.96 USD
  1. ALT alanine aminotransferase, IV intravenous, HCV hepatitis C virus, HIV human immunodeficiency virus, USD United States dollars